Clicky

Lonza Group AG(LONN)

Description: Lonza Group AG, together with its subsidiaries, supplies various products and services for pharmaceutical, biotech, and nutrition markets in Europe, North and Central America, Latin America, Asia, Australia and New Zealand, and internationally. It operates through Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients segments. The Biologics segment engages in the contract development and manufacturing of biopharmaceuticals for clinical and commercial manufacturing needs throughout the product lifecycle, including drug substance and drug product manufacturing. The Small Molecules segment operates as an integrated development and manufacturing service provider for small molecule drug substances and their intermediates. It supports customers across various aspects of design, development, and manufacturing. The Cell & Gene segment develops technologies and platforms that industrialize the manufacturing processes and production of cell and gene therapies. It also offers contract development and manufacturing services, and regulatory support for a range of allogeneic and autologous cell therapies, and exosome-based therapies, as well as viral vector gene therapies. In addition, this segment provides specialty raw materials and enabling technology solutions in cell and gene therapy, injectable drugs, vaccines, and bio-manufacturing markets. The Capsules & Health Ingredients segment offers capsules, dosage form solutions, and health ingredients for pharmaceutical and nutraceutical customers. The company was founded in 1897 and is headquartered in Basel, Switzerland.


Keywords: Biotechnology Biopharmaceutical Life Sciences Biology Pharmacy Technology Solutions Gene Therapy Manufacturing Services Manufacturing Processes Lonza Group Manufacturing Service Clinical And Commercial Manufacturing

Home Page: www.lonza.com

Muenchensteinerstrasse 38
Basel, 4002
Switzerland
Phone: 41 61 316 81 11


Officers

Name Title
Dr. Pierre-Alain Ruffieux Ph.D. Chief Exec. Officer
Mr. Philippe Deecke Chief Financial Officer
Ms. Maria Soler Nunez Head of Group Operations
Mr. Dirk Oehlers VP of Investor Relations
Mr. Andreas Bohrer Group Gen. Counsel & Company Sec.
Ms. Victoria Morgan Head of External Communications
Ms. Jennifer Clancy Sr. Director of Global Marketing
Dr. Caroline Barth M.D. Chief HR Officer
Ms. Constance Ward Head of External Communications
Dr. Sanna Fowler Head of External Communications

Exchange: SW

Country: CH : Switzerland

Currency: Swiss Franc (CHF)

Forward PE: 26.455
Trailing PE: 39.0024
Price-to-Book MRQ: 3.3889
Price-to-Sales TTM: 5.8131
IPO Date:
Fiscal Year End: December
Full Time Employees: 17154
Back to stocks